NCT01113112Completed
Biobehavioral-Cytokine Interactions in Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 6 Feb 2026
Brief summary (registry, in English)
The purpose of this study is to understand relationships between behavioral factors, hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 613 (actual)
- First submitted
- 27 Apr 2010
- Start date
- Aug 2003
- Primary completion date
- 10 Nov 2015
- Lead sponsor
- Susan Lutgendorf
- Diseases
- Ovarian cancer
- NCT number
- NCT01113112
What you commit to
- Study type: Observational
- Participants enrolled: 613
- From Aug 2003 to the primary completion date, 10 Nov 2015
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a diagnosis of borderline epithelial ovarian tumor (formerly: tumors of low malignant potential" or recurrent invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer treated with chemotherapy or radiotherapy previously are excluded.
- Patients who received neoadjuvant chemotherapy for ovarian, primary peritoneal, or fallopian tube carcinoma are excluded.
Other illness
- Non-epithelial ovarian cancers or metastases to the ovaries from organs are excluded.
- Previous cancer diagnosis except for basal cell carcinoma of the skin or history of lymphoma.
- Comorbid conditions: Addison's disease, autoimmune hepatitis, hepatitis B, hepatitis C, AIDS or HIV, lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis.
- Inability to accurately answer questions (e.g. a condition such as dementia)
Age
- Pregnancy or age \<18 years old
Other
- Use of systemic glucocorticoids such as prednisone or decadron in the last 30 days
Who the study is looking for
- Patients with a histologic diagnosis of epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer; FIGO stage I to IV defined surgically at the completion of the initial abdominal surgery and with appropriate tissue available for histologic evaluation.
- Patients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell carcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified. However, the histologic features must be compatible with primary Mullerian epithelial adenocarcinoma.
- GOG performance status 0-3
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Iowa Hospitals and Clinics Coordinator of this site? Confirm its status | Iowa City | United States | Unknown status |
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.